VERDESO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6730288 | ALMIRALL | Mousse composition |
Sep, 2019
(4 years ago) | |
| US7029659 | ALMIRALL | Mousse composition |
Sep, 2019
(4 years ago) | |
| US9492384 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(1 year, 4 months from now) | |
| US8962000 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(1 year, 4 months from now) | |
| US8460641 | ALMIRALL | Microemulsion process and composition |
Aug, 2027
(3 years from now) | |
Verdeso is owned by Almirall.
Verdeso contains Desonide.
Verdeso has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Verdeso are:
- US6730288
- US7029659
Verdeso was authorised for market use on 19 September, 2006.
Verdeso is available in aerosol, foam;topical dosage forms.
Verdeso can be used as treatment of atopic dermatitis.
The generics of Verdeso are possible to be released after 13 August, 2027.
Drugs and Companies using DESONIDE ingredient
Market Authorisation Date: 19 September, 2006
Treatment: Treatment of atopic dermatitis
Dosage: AEROSOL, FOAM;TOPICAL
More Information on Dosage
VERDESO family patents
